Landin, M. Int. J. Pharm. 104(3), 271-5, 1994.* |
Takami, Kiyoshi Chem. Pharm. Bull. 44(4), 868-70, 1996.* |
Otsuka, Makoto J. Biomed. Mater. Res. 29(1), 25-32, 1995.* |
Bavitz and Shiromani, 1986, “Granulation surface area as basis for magnesium stearate concentrations in tablet formulations”, Drug Dev. Ind. Pharm. 12:2481-2492. |
Ip et al., 1992, “Lisinopril”, Analytical Profiles Of Drug Substances And Excipients vol. 21 (Academic Press) pp. 233-276. |
Landin et al., 1994, “Chemical stability of acetylsalicylic acid tablets prepared with different commercial brands of dicalcium phosphate dihydrate”, Int. J. Pharmaceutics 107:247. |
Landin et al., 1994, “Dicalcium phosphate dihydrate for direct compression: characterization and intermanufacturer variability”, Int. J. Pharmaceutics 109:1-8. |
Landin, 1995, “Chemical stability of acetylsalicylic acid in tablets prepared with different particle size fractions of a commercial brand of dicalcium phosphate dihydrate”, Int. J. Pharmaceutics 123:143-144. |
Shiromani and Bavitz, 1988, “Studies on a dibasic calcium phosphate-mannitol matrix table formulation —a complementary combination”, Drug Dev. Ind. Pharm. 14:1375-1387. |
Wang et al., 2000, “Thermal-Dependent Dehydration Process and Intramolecular Cyclization of Lisinopril Dihydrate in the Solid State”, Chem. Pharm. Bull. 48:1890-1893. |